Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- JT to Cease Development of Osteoporosis Treatment following Termination of License Agreement with Merck
October 19, 2011
- UCB Japan Reorganizes Sales & Marketing Division to Enhance Specialization
October 19, 2011
- SSP Aims for 10% Market Share with Switch OTC Alesion 10
October 19, 2011
- Japan, a Strategic Country Where Growth is Expectable: New AZ President Hudson
October 18, 2011
- MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
- MTPC Aims to Initiate Clinical Studies for 3 Compounds per Year
October 18, 2011
- Torii Upwardly Revises Profit Forecast for 1st Half of FY2012
October 18, 2011
- Eisai, Johns Hopkins Univ. Agree on Neurological Drug Discovery Collaboration
October 18, 2011
- OncoTherapy Science to Start Clinical Trial for Cancer Treatment Antibody in France
October 18, 2011
- Takeda Appoints Davidsen Head of Emerging Markets, Nycomed
October 18, 2011
- R-Tech Ueno to Resume Development of Treatment for Dry Eye
October 18, 2011
- NBI, Eli Lilly Japan to Establish “Special Position” for Trazenta in DPP-4 Inhibitor Market
October 18, 2011
- US MediciNova to Jointly Conduct Clinical Trials of MN-221 with Kissei
October 17, 2011
- Bayer, Onyx Restructure Global Oncology Partnership
October 17, 2011
- Ube, Santen Enter into License Agreement for EP2 Agonist
October 17, 2011
- MTPC Licenses Novel Pruritus Treatment from Toray in North America
October 17, 2011
- Otsuka Medical Devices to Acquire KiSCO Group Companies
October 17, 2011
- IBL Launches ANGPTL2 Assay Kit
October 17, 2011
- 60% Rule Likely to Replace 70% Rule for New Generics: Mr Kikuchi of Nichi-Iko MPI
October 17, 2011
- CMIC Forms a Chinese Joint Venture, Making Capital Investment in Local CRO
October 14, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…